1. Type 2 Diabetes and Bone Disease
   Norma Lopez et al, 2023, Clinical Reviews in Bone and Mineral Metabolism CrossRef
2. Liraglutide Inhibits Osteoclastogenesis and Improves Bone Loss by Downregulating Trem2 in Female Type 1 Diabetic Mice: Findings From Transcriptomics
   Jie Yu et al, 2021, Frontiers in Endocrinology CrossRef
3. Negligible Effect of Estrogen Deficiency on Development of Skeletal Changes Induced by Type 1 Diabetes in Experimental Rat Models
   Aleksandra Janas et al, 2020, Mediators of Inflammation CrossRef
4. Anomalous bone changes in ovariectomized type 2 diabetic rats: inappropriately low bone turnover with bone loss in an estrogen-deficient condition
   Ratchaneevan Aeimlapa et al, 2019, American Journal of Physiology-Endocrinology and Metabolism CrossRef
5. The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
   Baocheng Xie et al, 2021, Frontiers in Pharmacology CrossRef
6. Liraglutide Attenuates Hepatic Oxidative Stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic Mice by Modulating the Wnt/β-Catenin Signaling Pathway
   Jie Yu et al, 2023, Mediators of Inflammation CrossRef
7. Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes
   Zongyi Wu et al, 2024, Frontiers in Endocrinology CrossRef
8. Liraglutide in Combination with Insulin Has a Superior Therapeutic Effect to Either Alone on Fracture Healing in Diabetic Rats
   Hao Liu et al, 2023, Diabetes, Metabolic Syndrome and Obesity CrossRef
9. Vertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females
   Xuefeng Li et al, 2024, Frontiers in Endocrinology CrossRef
10. Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis
    Hee‐Ju Kim et al, 2024, Diabetes/Metabolism Research and Reviews CrossRef